FEATURED EDITORIAL
Thymic stromal lymphopoietin (TSLP) inhibition has firmly established itself as a strategy in respiratory disease. This article highlights some promising drug candidates and next-generation approaches.
- What If The U.S. Government Stopped Funding Biotech?
- What's Next For ADCs: How Combinations Will Help Define The Future Of Treatment
- 5 Takeaways From The Boston Open Science & Innovation Forum
- From "Live Drug" To Precision Tool: Redefining CAR T Safety
- NAMs In France And Europe: The Current Landscape
- Rethinking Tau Biology: The Future Of Neurodegenerative Drug Discovery
- Proteomics Biomarkers Beyond Blood
FEATURED APPLICATION CONTENT
-
Explore how leveraging expert CDMO partnerships can streamline the development process and enhance the efficacy of your bispecific antibody therapies.
-
Consider this alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and how we're leveraging it for COVID-19 antibody discovery.
-
By forging strategic partnerships with comprehensive CDMOs, see how emerging biopharma firms can navigate through early-phase development and ensure a smooth transition to clinical advancement.
-
Explore how advanced single‑cell analysis links CAR localization, cell structure, and functional behavior, offering deeper insight into CAR T cell heterogeneity and performance.
-
Gain insight into automating DNA size selection that shows how optimized bead ratios and programmable handling improve fragment recovery, consistency, and throughput.
-
Gain insight into an automated high‑input workflow that streamlines long‑read whole‑genome library prep, supporting large DNA fragments while reducing reagent use.
-
A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.
-
Understanding covalent warhead kinetics is key to reducing safety risks early in discovery. Learn about a new approach to GSH‑based measurements that offers clearer predictors of toxicity.
-
See how a rapid digital PCR workflow enables reliable detection of trace RCL levels while maintaining strong performance in complex samples, which support more confident decisions in manufacturing.
-
Discover how mixed-mode chromatography enables high-yield purification of single-domain antibodies under mild conditions and why these approaches outperform traditional resins.
-
Scalable lentiviral vector production is moving beyond adherent systems. Learn how streamlined workflows enable linear scale-up in stirred-tank bioreactors for cost-effective gene therapy manufacturing.
-
Decoding immune cell interactions reveals critical insights for cancer therapy. Advanced imaging and spectral analysis enable precise identification of synapses, accelerating immuno-oncology research.
- 5 Takeaways From The Boston Open Science & Innovation Forum
- Video Spotlight: Harvard's Alice Stanton On Engineering Integrated Human-Derived miBrain Organoid Models
- Insights From The Non-Opioid Pain Therapeutics Summit: Human-Centric Translational Models And The Reawakening Of Pain Pipelines
- Schrödinger's Equation Turns 100: How Quantum Chemistry Is Improving Drug Discovery
- Annual Reflections And Predictions From The Editors' Roundtable
DRUG DISCOVERY CONTENT COLLECTIONS
Drug discovery is moving beyond traditional hit identification toward data-driven strategies that extract deeper insight from large-scale screening datasets. Advances in DNA-encoded library (DEL) screening, computational tools, and machine learning are helping teams make more informed decisions in early-stage drug development. Access this brand-new Drug Discovery Online content collection for an under-the-hood look at modern approaches to turning large discovery datasets into actionable insight.
FEATURED NEWS HEADLINES
- Flagship Pioneering And AWS Announce Collaboration To Accelerate Drug Discovery And Life Sciences Innovation
- Cogent Biosciences Announces Submission Of New Drug Application For Bezuclastinib In Gastrointestinal Stromal Tumors (GIST)
- Quantum Biopharma Submits Investigational New Drug (IND) Application To United States Food And Drug Administration (FDA) For Lucid-MS Phase Two Clinical Trial In Multiple Sclerosis
- NJ Bio, Inc. And Ajinomoto Bio Pharma Services Enter Into Collaboration To Strengthen Support For Antibody-Drug Conjugate Development
- Lupin Receives Tentative Approval From U.S. FDA For Sugammadex Injection
- OpenProtein.AI Expands Strategic Partnership With Boehringer Ingelheim To Advance AI-Driven Antibody Discovery
- Asha Therapeutics Launches As First Atom Therapeutics, A Zero-Shot De Novo Drug Design Company
- Zymeworks Receives U.S. FDA Fast Track Designation For ZW191, An Frα-Targeting Antibody-Drug Conjugate
- Jyong Biotech Updates The Potential Clinical Benefits And Advantages Of Its Plant-Derived Innovative Drug MCS®-2
- IBM Quantum Computer Accurately Simulates Real Magnetic Materials, Reproducing National Laboratory Data
ARCHIVED NEWSLETTER
- 03.31.26 -- AI For NAM-Ready Drug Development: Turning Promise Into Trust
- 03.24.26 -- 5 Takeaways From The Boston Open Science & Innovation Forum
- 03.17.26 -- Hibernating Squirrels May Hold Clues To Treating Heart Failure
- 03.07.26 -- Drug Discovery Online Best Of February
- 03.03.26 -- In Vivo LNP-Engineered Cytokine-Armored CAR Cells For Solid Tumors
